Eisai Divests U.S., Puerto Rico Zonegran Rights To Concordia
This article was originally published in PharmAsia News
Eisai has divested U.S. and Puerto Rico marketing and distribution rights to the Zonegran (zonisamide) anti-epilepsy drug to U.S.-based Concordia Pharmaceuticals.
You may also be interested in...
After a stunning first efficacy readout for its mRNA-based vaccine, the biotech company's leaders in Europe talk about their rapid commercial and manufacturing scale-up.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.